Get the Stockscreener App
1.74
0.00%
0.01
Nkarta Inc stock is traded at $1.74, with a volume of 42,785.
It is up +0.00% in the last 24 hours and down -27.62% over the past month.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
See More
Previous Close:
$1.73
Open:
$1.72
24h Volume:
42,785
Relative Volume:
0.05
Market Cap:
$123.95M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.725
EPS:
-2.4
Net Cash Flow:
$-114.31M
1W Performance:
-7.49%
1M Performance:
-27.62%
6M Performance:
+1.76%
1Y Performance:
-29.10%
1-Day Range:
$1.72
$1.755
1-Week Range:
$1.71
$1.90
52-Week Range:
$1.31
$3.1553
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
1.745 | 122.88M | 0 | -117.50M | -114.31M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.69 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.57 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.79 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
923.04 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
197.63 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
How interest rate cuts could boost Nkarta Inc. stockMarket Activity Report & Low Risk Growth Stock Ideas - newser.com
Why Nkarta Inc. stock appeals to dividend seekers2025 Retail Activity & High Accuracy Swing Entry Alerts - newser.com
Using Python tools to backtest Nkarta Inc. strategiesWeekly Gains Summary & High Conviction Buy Zone Picks - newser.com
Will Nkarta Inc. stock split again soonJuly 2025 Highlights & Risk Controlled Stock Alerts - newser.com
How Nkarta Inc. stock benefits from strong dollarOil Prices & Reliable Trade Execution Plans - newser.com
A better buy-in window may exist right now for Nkarta Inc (NKTX) - Setenews
What momentum indicators show for Nkarta Inc. stockTrade Analysis Summary & Daily Profit Maximizing Tips - newser.com
Is it time to cut losses on Nkarta Inc.Product Launch & Comprehensive Market Scan Reports - newser.com
Will Nkarta Inc. stock deliver strong dividend growthSwing Trade & Free Expert Verified Stock Movement Alerts - newser.com
Nkarta, Inc.Common Stock (NQ: NKTX - FinancialContent
Will Nkarta Inc. stock sustain high P E ratiosJuly 2025 Intraday Action & Short-Term Trading Alerts - newser.com
Nkarta reports Q3 EPS (29c), consensus (30c) - MSN
Nkarta Inc. stock prediction for this weekJuly 2025 Summary & Daily Price Action Insights - newser.com
Will Nkarta Inc. stock beat EPS estimatesPortfolio Risk Report & Safe Entry Zone Tips - newser.com
Published on: 2025-11-14 17:50:20 - newser.com
What is William Blair’s Forecast for Nkarta FY2025 Earnings? - Defense World
Q1 Earnings Estimate for Nkarta Issued By Leerink Partnrs - Defense World
William Blair Forecasts Nkarta’s Q1 Earnings (NASDAQ:NKTX) - Defense World
FY2025 EPS Estimates for Nkarta Lifted by Leerink Partnrs - Defense World
Published on: 2025-11-13 17:41:50 - newser.com
Risk adjusted return profile for Nkarta Inc. analyzedWeekly Trade Review & Free Fast Entry Momentum Trade Alerts - newser.com
HC Wainwright Forecasts Nkarta’s Q1 Earnings (NASDAQ:NKTX) - Defense World
Nkarta CEO Paul Hastings sells $38,231 in stock - MSN
Nkarta price target lowered to $11 from $12 at Stifel - MSN
Nkarta (NKTX) Receives a Buy from H.C. Wainwright - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), BioLife Solutions (BLFS) and Cardiff Oncology (CRDF) - The Globe and Mail
Published on: 2025-11-12 02:36:29 - newser.com
Nkarta (NKTX) Upgraded to Buy: Here's Why - MSN
Nkarta Inc (NKTX) is looking forward to a strong quarter - Setenews
Stifel lowers Nkarta stock price target to $11 from $12, keeps Buy rating - Investing.com Canada
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nkarta Inc Stock (NKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shook David | See Remarks |
Jan 15 '25 |
Sale |
2.20 |
8,638 |
19,004 |
190,955 |
| Levin Alyssa | See Remarks |
Jan 15 '25 |
Sale |
2.20 |
5,838 |
12,844 |
102,662 |
| Brandenberger Ralph | Chief Technical Officer |
Jan 15 '25 |
Sale |
2.20 |
7,447 |
16,383 |
124,796 |
| HASTINGS PAUL J | Chief Executive Officer |
Jan 15 '25 |
Sale |
2.20 |
17,378 |
38,232 |
319,859 |
| Hager Alicia J. | Chief Legal Officer |
Jan 15 '25 |
Sale |
2.20 |
9,584 |
21,085 |
146,735 |
0.52%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):